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Ovary cancer risk in relation to consumption of dairy products was investigated using a self-administered questionnaire on dietary
habits and other risk factors for cancer, which was completed in 1986 by 62573 postmenopausal women participating in the
Netherlands Cohort Study. Follow-up for cancer was implemented by annual record linkage with the Netherlands Cancer Registry
and a nationwide pathology registry. After 11.3 years of follow-up, data of 252 incident epithelial ovarian cancer cases and 2216
subcohort members were available for analysis. No association was seen between consumption of milk, yoghurt, cheese or
fermented dairy products and ovarian cancer risk. The multivariable adjusted relative risk of epithelial ovarian cancer for women in the
highest compared to the lowest quintile of intake of lactose or dairy fat was 0.93 (95% confidence interval (CI)¼0.60–1.45;
Ptrend¼0.32) and 1.53 (95% CI¼1.00–2.36; Ptrend¼0.11), respectively. Lactose or dairy fat intakes were not associated with serous
ovarian cancer risk. Our results do not support an association between consumption of dairy products or lactose intake and ovarian
cancer.
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Ovarian cancer ranks fifth as the most common malignancy among
women in Europe, with approximately 34500 newly diagnosed
ovarian cancer cases in 1998 (Ferlay et al, 1999). Due to its late
detection in many cases, survival rates are low.
In an ecological analysis, ovarian cancer incidence and per
capita milk consumption have been found to be correlated among
populations (Cramer, 1989). The results from case–control and
prospective cohort studies regarding milk consumption and
ovarian cancer risk have been inconsistent (Mettlin and Piver,
1990; Webb et al, 1998; Kushi et al, 1999; Cramer et al, 2000;
Goodman et al, 2002; Fairfield et al, 2004; Larsson et al, 2004; Qin
et al, 2005).
As a possible mechanism underlying the effect of milk
consumption on ovarian cancer risk, metabolites of the milk-
sugar lactose have been suggested (Cramer, 1989; Cramer et al,
1989). With the exception of two case–control studies that
reported a protective effect (Herrinton et al, 1995; Goodman
et al, 2002), most studies found no statistically significant effect of
high lactose intake on overall ovarian cancer risk (Engle et al,
1991; Webb et al, 1998; Kushi et al, 1999; Cramer et al, 2000; Cozen
et al, 2002; Fairfield et al, 2004). On the other hand, for serous
epithelial ovarian tumours, a positive association with lactose
intake has been observed (Fairfield et al, 2004; Larsson et al, 2004).
Most attention has been given to lactose even though other
components of milk and milk products may be involved, such as
dairy fat (Cramer et al, 1984; Qin et al, 2005), which may also be
considered as a candidate risk factor because it is believed to exert
an effect through hormone-related mechanisms.
To investigate whether consumption of dairy products (such as
milk, yoghurt or cheese), its components (such as lactose or dairy
fat) or its processing (fermentation) is associated with epithelial
ovarian cancer risk, we used data from a large prospective
cohort study conducted among postmenopausal women in the
Netherlands, a country with high consumption of dairy products.
MATERIALS AND METHODS
The cohort
The Netherlands Cohort Study on Diet and Cancer is a prospective
cohort study that started in September 1986 with the enrolment
of 120852 subjects (62573 females) aged between 55 and 69 years
from 204 municipalities with computerised population registries,
located throughout the country. A detailed description of the study
design has been published elsewhere (van den Brandt et al, 1990a).
In brief, a case–cohort approach was used for data processing and
analysis. Cases were enumerated from the entire cohort, whereas
accumulated person-years for the entire cohort were estimated
using a subcohort of 5000 participants, 2589 of whom were
females. The subcohort was randomly sampled from the cohort
after baseline exposure measurement and followed up biennially
for vital status information. After 11.3 years of follow-up,
information on vital status was available for all female subcohort
members. After exclusion of women with prevalent cancer (other
than skin cancer) at baseline and those who at baseline had
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subcohort members remained available for analyses.
Identification of cases
Incident cancer cases were identified by computerised record
linkage of the entire cohort to the regional cancer registries and to
the nationwide network and registry of histo- and cytopathology
in the Netherlands (PALGA) (van den Brandt et al, 1990a,b). The
completeness of cancer follow-up has previously been estimated to
be over 95% (Goldbohm et al, 1994b). During 11.3 years of follow-
up, 300 incident, microscopically confirmed, primary ovarian
cancer cases (ICD-O-3:C56.9) were identified. After excluding
nonepithelial tumours (n¼9) and borderline invasive epithelial
tumours (n¼9), 282 invasive epithelial tumour cases remained
available for analyses. Of these 282 epithelial ovarian cancers, 138
were serous carcinoma (ICD-O: 8260, 8441-8462, 9014).
Questionnaire
Information on dietary habits and such potential confounders, as
smoking behaviour, reproductive history, and family history of
cancer, was collected at baseline, from all cohort members, using a
self-administered questionnaire. This included a 150-item semi-
quantitative food frequency questionnaire, assessing regular
food and beverage consumption in the year preceding the start
of the study, which had been validated against a 9-day diet record,
attaining Spearman’s correlation coefficients of 0.60 for milk and
milk products and 0.61 for cheese (Goldbohm et al, 1994a).
Data were obtained on frequency of dairy consumption (i.e.,
milk, yoghurt, cheese, curds, custard, oatmeal, butter, and pudd-
ing) and amount consumed on each consumption day (number of
glasses for milk, number of slices of bread for cheese, and number
of bowls for yoghurt, oatmeal, etc.). Consumption frequency was
recorded using categories ranging from ‘never or less than once
per month’ to ‘six or seven times per week’.
Sources of fermented milk and milk products were investigated,
including yoghurt, buttermilk, fat cheese, and curds; for non-
fermented milk and milk products these were milk and cream.
Sources of lactose were yoghurt, milk, chocolate, butter, dry curd,
custard, pudding, and oatmeal.
Data analyses
After excluding subjects with incomplete or inconsistent dietary
data (Goldbohm et al, 1994a), 252 ovarian cancer cases and 2216
subcohort members remained for analysis. Subjects were grouped
into categories of dairy consumption (i.e., total milk, total yoghurt,
and total cheese) and into quintiles of intake of lactose, dairy fat,
fermented milk and milk products, and non-fermented milk and
milk products, based on the distribution in the subcohort.
We examined if other risk factors (oral contraceptives use,
(post)menopausal hormone therapy, parity, height, weight, body
mass index, family history of ovarian or breast cancer, hyste-
rectomy, age at menarche, age at menopause, tubal ligation,
smoking behaviour, and socioeconomic status) were confounders
in our data. Risk factors were considered to be confounders if
they were associated with ovarian cancer risk, were associated
with dairy intake, and, after inclusion in the model, changed the
association of dairy with the risk of ovarian cancer by more than
10% compared to the model not including this factor. As a result,
multivariable analyses included age (years), height (continuous),
current cigarette smoker (y/n), duration of cigarette smoking
(years), number of cigarettes smoked daily (continuous), duration
of oral contraceptives use (years), and parity (continuous) as
confounders.
Person-years of follow-up were calculated for the female
subcohort members from the date they returned the questionnaire
(September 1986) until the date of ovarian cancer diagnosis, death,
or end of follow-up (December 1997).
Incidence rate ratios (RR) and corresponding 95% confidence
intervals (CI) for ovarian cancer risk were estimated in age-
adjusted and multivariate case–cohort analyses using Cox
proportional hazards model (Cox, 1972) processed with the
STATA statistical software package (Cleves et al, 2002). Standard
errors were estimated using the robust Huber–White sandwich
estimator to account for additional variance introduced by
sampling from the cohort (Lin and Wei, 1989). The proportional
hazards assumption was tested using the scaled Schoenfeld (1982)
residuals. By fitting ordinal exposure variables as continuous
terms, tests for dose-response trends in risks of ovarian cancer
were carried out. Two-sided P-values are reported throughout the
paper and considered statistically significant if o0.05.
RESULTS
During 11.3 years of follow-up of 62573 women, 282 epithelial
ovarian cancer cases occurred, 252 of which were in women with
complete and consistent dietary data. Of these 252 epithelial
ovarian cancers, 126 were of the serous subtype.
Mean total dairy consumption as well as mean lactose intake
were higher among women who reported ever use of oral
contraceptives than among women who did not (Table 1), and
was lower in current smokers than in nonsmokers. Taller women
(4170cm) also reported higher dairy consumption than those of
lesser height (o160cm). Lactose was highly correlated with total
milk (r¼0.73) intake, especially with respect to nonfermented
milk and milk products (r¼0.82). The correlation coefficient for
dairy fat with total cheese was 0.46 and with total milk 0.27.
Table 2 shows the age-adjusted and multivariable-adjusted RR
for ovarian cancer according to categories of milk, yoghurt, or
cheese consumption. After adjusting for confounders, women in
the highest category of total milk (RR¼0.98, 95% CI¼0.65–1.48),
total yoghurt (RR¼0.87, 95% CI¼0.59–1.28), or total cheese
(RR¼1.06, 95% CI¼0.54–2.08) consumption were not at greater
risk of ovarian cancer compared to women in the lowest
consumption category. Serous epithelial ovarian cancers did not
show an association with the dairy products investigated.
No statistically significant association was found with consump-
tion of fermented or nonfermented milk and milk products
(Table 2). Only the highest quintile of dairy fat intake was
associated with increased risk when compared to the lowest
quintile of intake (RRQ5 vs Q1¼1.53, 95% CI¼1.00–2.36;
Ptrend¼0.11). This positive association was not seen for serous
epithelial ovarian cancer (RRQ5 vs Q1¼0.76, 95% CI¼0.42–1.39).
The numbers of other subtypes of epithelial ovarian cancer were
too small to allow for separate analyses. The frequencies of all
subtypes of epithelial ovarian cancer were uniformly distributed
over the fat quintiles, with the exception of the endometrioid
subtype (n¼24), for which the frequency increased over the
quintiles of dairy fat intake (data not shown).
Higher intake of lactose showed no association or at most a
tendency towards decreased risk (for all ovarian cancers
Ptrend¼0.32 and for serous ovarian cancer Ptrend¼0.11), largely
due to a significantly decreased risk in the third quintile of intake
for all epithelial ovarian cancers (RRQ3 vs Q1¼0.62, 95% CI¼0.39–
0.98) as well as for serous ovarian cancers (RRQ3 vs Q1¼0.45, 95%
CI¼0.22–0.91). The multivariable adjusted RR for lactose of the
epithelial ovarian cancers or its serous subtype did not importantly
change after additionally adjusting for dietary fat, energy, or total
milk intake, respectively.
In addition, we investigated if the presence of subclinical disease
at baseline had influenced our results, and re-analysed our data
after excluding cases and subcohort members with less than 2
years of follow-up; this did not substantially change our results.
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In this large prospective cohort study of postmenopausal Dutch
women, no relation between consumption of milk, yoghurt, or
cheese and ovarian cancer risk was seen. In contrast to the
previously reported results from cohort studies (Fairfield et al,
2004; Larsson et al, 2004), in the present study, lactose intake was
not positively associated with serous ovarian cancer. The highest
quintile of dairy fat intake was associated with increased ovarian
cancer risk when compared to the lowest intake, but no statistically
significant dose–response relation was observed and it was absent
for serous ovarian cancers.
Table 1 Mean (7s.d.) daily consumption of dairy products and lactose intake in the subcohort (n¼2216), according to potential risk factors for ovarian
cancer (recorded at baseline), Netherlands Cohort Study on Diet and Cancer, 1986–1997
Total dairy Lactose
Characteristics n (%) Mean (7s.d.)
a Mean (7s.d.)
a
Age (years)
55–59 860 (38.8) 304.5 (196.1) 14.6 (8.5)
60–64 744 (33.6) 298.1 (179.6) 14.3 (7.8)
65–69 612 (27.6) 293.4 (188.2) 14.3 (8.3)
Ever use of oral contraceptives
No 1643 (75.1) 293.4 (190.8) 14.2 (8.3)
Yes 545 (24.9) 319.6 (180.1) 15.3 (8.0)
Ever use of (post)menopausal hormone therapy
No 1838 (86.9) 296.2 (188.1) 14.3 (8.2)
Yes 277 (13.1) 318.2 (189.3) 15.2 (8.2)
Parity
0 children 398 (18.2) 298.9 (189.3) 14.2 (8.1)
1 child 179 (8.2) 296.2 (191.8) 14.6 (8.8)
2 children 472 (21.6) 301.3 (193.5) 14.2 (8.4)
42 children 1136 (52.0) 298.7 (184.2) 14.5 (8.0)
Hysterectomy
No 1838 (82.9) 296.4 (189.4) 14.3 (8.3)
Yes 378 (17.1) 313.5 (183.8) 15.0 (8.1)
Family history of ovarian and/or breast cancer
b
No 2023 (91.3) 301.0 (188.7) 14.5 (8.3)
Yes 193 (8.7) 281.2 (185.3) 13.5 (8.0)
Tubal ligation
No 2206 (99.6) 299.2 (188.7) 14.4 (8.2)
Yes 10 (0.4) 310.7 (138.1) 14.5 (5.4)
Age at menarche (years)
p12 569 (26.0) 293.3 (183.7) 14.0 (8.0)
13–14 995 (45.4) 303.3 (190.1) 14.6 (8.4)
X15 626 (28.6) 300.5 (188.4) 14.6 (8.1)
Age at menopause (years)
p44 327 (15.8) 279.3 (182.2) 13.6 (8.0)
45–49 671 (32.5) 300.6 (185.8) 14.6 (8.1)
50–54 910 (44.0) 308.1 (193.3) 14.8 (8.5)
X55 158 (7.7) 291.2 (185.5) 14.2 (8.3)
Current cigarette smoking
No 1746 (78.8) 304.3 (184.8) 14.6 (8.0)
Yes 470 (21.2) 280.5 (200.6) 13.8 (8.9)
Socioeconomic status (highest level of education)
Primary school 741 (33.6) 301.2 (182.7) 14.7 (8.1)
Lower vocational school 511 (23.2) 284.4 (176.6) 13.9 (7.7)
High school/intermediate vocational school 760 (34.5) 301.3 (199.8) 14.3 (8.7)
Higher vocational school/University 191 (8.7) 322.2 (189.8) 15.1 (8.2)
Height (in cm)
o160 510 (23.7) 272.2 (180.0) 13.2 (7.8)
160–164 403 (18.7) 282.9 (193.4) 13.7 (8.7)
164–167 428 (19.9) 314.2 (183.9) 15.1 (7.9)
167–170 441 (20.5) 299.8 (186.6) 14.6 (8.3)
4170 373 (17.3) 333.4 (193.0) 15.8 (8.4)
Due to missings, numbers do not always add up to the total.
aIn gday
 1.
bIn first degree relatives (mother, sister, daughter).
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the US cohort studies (Kushi et al, 1999; Fairfield et al, 2004) have
reported increased risk with higher consumption of milk. In the
Swedish Mammography Cohort Study, the risk was 1.3 (95%
CI¼0.9–1.9) for women who consumed X2 glasses milk per day
compared to never or seldom users, and this association was
stronger (RR¼2.0, 95% CI¼1.1–3.7) for serous ovarian cancer
(Larsson et al, 2004). In the Nurses’ Health Study, when skim or
low-fat and whole milk were considered separately, a significant
positive trend was only observed for skim or low-fat milk (Fairfield
et al, 2004). Higher consumption of skim milk was also found to
increase the risk of ovarian cancer in the Iowa Women’s Health
Table 2 Age-adjusted and multivariate RRs and 95% CI for ovarian cancer according to dairy consumption and intake of fat or lactose, Netherlands
Cohort Study on Diet and Cancer, 1986–1997
All invasive epithelial ovarian tumours Serous epithelial ovarian tumours
Median
Cases/
person
years
a RR (95% CI)
a
Cases/
person
years
b RR (95% CI)
b
Cases/
person
years
a RR (95% CI)
a
Cases/
person
years
b RR (95% CI)
b
Total milk (gday
 1)
0 0 86/8021 1.00 75/7347 1.00 44/8021 1.00 39/7347 1.00
0.1–o66.0 60 36/3677 0.91 (0.61–1.37) 33/3213 0.97 (0.63–1.50) 14/3677 0.69 (0.37–1.28) 12/3213 0.68 (0.35–1.32)
66.0–o150.1 119 33/3048 1.01 (0.66–1.55) 26/2733 0.95 (0.59–1.54) 21/3048 1.26 (0.74–2.16) 15/2733 1.04 (0.56–1.93)
150.1–o186.0 171 53/4778 1.02 (0.71–1.46) 49/4352 1.10 (0.75–1.62) 28/4778 1.04 (0.64–1.70) 26/4352 1.08 (0.64–1.81)
X186.0 343 44/4269 0.96 (0.66–1.41) 40/3849 0.98 (0.65–1.48) 19/4269 0.81 (0.47–1.41) 17/3849 0.79 (0.43–1.40)
P-trend 0.99 0.97 0.45 0.64
Total yoghurt (gday
 1)
0 0 69/6298 1.00 60/5677 1.00 37/6298 1.00 33/5677 1.00
0.1–o48.1 12 58/5507 1.00 (0.69–1.45) 54/4939 1.07 (0.72–1.59) 25/5507 0.80 (0.47–1.36) 22/4939 0.77 (0.44–1.35)
48.1–o96.2 53 58/4815 1.13 (0.78–1.64) 52/4473 1.11 (0.74–1.65) 34/4815 1.23 (0.76–1.99) 31/4473 1.16 (0.69–1.94)
X96.2 139 67/7174 0.88 (0.61–1.25) 57/6406 0.87 (0.59–1.28) 30/7174 0.73 (0.45–1.21) 23/6406 0.60 (0.34–1.05)
P-trend 0.61 0.63 0.19 0.1
Total cheese (gday
 1)
0 0 18/1754 1.00 15/1597 1.00 10/1754 1.00 9/1597 1.00
0.1–o12.9 7 61/5812 1.01 (0.58–1.76) 56/5160 1.21 (0.66–2.21) 28/5812 0.83 (0.40–1.75) 27/5160 0.93 (0.43–2.03)
12.9–o18.6 19 60/6254 0.92 (0.52–1.60) 53/5722 0.98 (0.53–1.81) 32/6254 0.88 (0.43–1.83) 26/5722 0.77 (0.35–1.69)
18.6–o37.1 31 82/6953 1.13 (0.66–1.94) 72/6297 1.20 (0.66–2.20) 39/6953 0.96 (0.47–1.97) 33/6297 0.86 (0.40–1.86)
X37.1 56 31/3022 1.01 (0.55–1.86) 27/2718 1.06 (0.54–2.08) 17/3022 0.99 (0.45–2.22) 14/2718 0.84 (0.35–2.03)
P-trend 0.85 0.8 0.97 0.96
Fermented milk and milk products (gday
 1)
0–o11 0 57/4759 1.00 52/4284 1.00 31/4759 1.00 28/4284 1.00
11–o53.4 28 49/4847 0.87 (0.58–1.30) 44/4375 0.81 (0.53–1.25) 20/4847 0.65 (0.36–1.15) 18/4375 0.62 (0.34–1.16)
53.4–o119.3 96 61/4745 1.10 (0.75–1.62) 52/4276 1.01 (0.67–1.53) 31/4745 1.02 (0.61–1.71) 25/4276 0.89 (0.51–1.57)
119.3–o192.7 144 43/4532 0.81 (0.53–1.23) 38/4195 0.72 (0.46–1.13) 22/4532 0.77 (0.44–1.34) 18/4195 0.63 (0.34–1.15)
X192.7 278 42/4911 0.74 (0.48–1.13) 37/4365 0.67 (0.42–1.06) 22/4911 0.71 (0.40–1.26) 20/4365 0.64 (0.35–1.18)
P-trend 0.31 0.26 0.40 0.37
Nonfermented milk and milk products (gday
 1)
0–o46 21 45/4736 1.00 40/4359 1.00 24/4736 1.00 22/4359 1.00
46–o115.8 77 49/4688 1.11 (0.72–1.69) 44/4158 1.16 (0.73–1.83) 22/4688 0.92 (0.51–1.67) 20/4158 0.93 (0.50–1.76)
115.8–o192.7 155 50/4810 1.09 (0.72–1.67) 42/4398 1.05 (0.66–1.67) 32/4810 1.31 (0.76–2.26) 25/4398 1.10 (0.60–2.02)
192.7–o292.0 230 61/4811 1.32 (0.88–1.98) 55/4337 1.32 (0.85–2.04) 27/4811 1.07 (0.61–1.89) 24/4337 1.01 (0.55–1.84)
X292.0 375 47/4750 1.05 (0.68–1.61) 42/4244 1.04 (0.65–1.65) 21/4750 0.87 (0.48–1.58) 18/4244 0.76 (0.40–1.47)
P-trend 0.71 0.70 0.63 0.85
Dairy fat (gday
 1)
0–o7.9 5 47/5191 1.00 43/4649 1.00 29/5191 1.00 28/4649 1.00
7.9–o12.7 10 49/5052 1.07 (0.70–1.63) 44/4731 0.98 (0.63–1.53) 26/5052 0.92 (0.53–1.58) 23/4731 0.75 (0.42–1.33)
12.7–o19.4 15 46/4776 1.07 (0.70–1.64) 40/4256 1.00 (0.63–1.59) 22/4776 0.82 (0.46–1.45) 18/4256 0.64 (0.35–1.19)
19.4–o31.0 24 46/4685 1.07 (0.70–1.64) 40/4231 0.92 (0.58–1.47) 24/4685 0.90 (0.52–1.56) 20/4231 0.67 (0.37–1.22)
X31.0 40 64/4091 1.70 (1.14–2.54) 56/3628 1.53 (1.00–2.36) 25/4091 1.04 (0.60–1.80) 20/3628 0.76 (0.42–1.39)
P-trend 0.04 0.11 0.94 0.63
Lactose (gday
 1)
0–o7.7 5 59/4759 1.00 52/4310 1.00 29/4759 1.00 25/4310 1.00
7.7–o11.7 10 49/4824 0.82 (0.55–1.22) 44/4393 0.87 (0.57–1.33) 31/4824 1.06 (0.63–1.79) 28/4393 1.11 (0.64–1.94)
11.7–o15.6 14 39/4755 0.66 (0.43–1.01) 33/4410 0.62 (0.39–0.98) 16/4755 0.55 (0.30–1.03) 12/4410 0.45 (0.22–0.91)
15.6–o21.1 18 57/5196 0.89 (0.61–1.31) 52/4620 0.92 (0.61–1.40) 29/5196 0.92 (0.54–1.57) 27/4620 0.95 (0.54–1.68)
X21.1 26 48/4260 0.92 (0.61–1.38) 42/3762 0.93 (0.60–1.45) 21/4260 0.81 (0.46–1.45) 17/3762 0.72 (0.37–1.38)
P-trend 0.41 0.32 0.29 0.11
aAge-adjusted analyses.
bAnalyses adjusted for age (years), height (cm), current cigarette smoker (y/n), duration of cigarette smoking (years), number of cigarettes smoked daily,
duration of oral contraceptive use (years) and parity (continuous), and fermented dairy products and nonfermented dairy products for each other.
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studies have been inconsistent, some reporting no association with
whole milk (Cramer et al, 2000; Goodman et al, 2002) or skim or
low-fat milk (Cramer et al, 2000), whereas a positive association
with whole milk and a negative association with skimmed milk
have also been found (Mettlin and Piver, 1990; Webb et al, 1998).
For consumption of yoghurt, a positive association with serous
ovarian cancer was reported from the Nurses’ Health Study, and
for consumption of hard cheese the risk of all epithelial ovarian
tumours was decreased with higher consumption (Fairfield et al,
2004). The results of our prospective cohort study are in
accordance with results from previous case–control studies
(Cramer et al, 2000; Goodman et al, 2002) in showing no
effect of higher yoghurt or cheese consumption on ovarian
cancer risk.
Lactose or dairy fat has been considered as the explanation for
earlier findings of increased ovarian cancer risk with higher
consumption of dairy products. In this regard, lactose and in
particular its metabolite galactose have attracted most attention,
since ovaries may be prone to galactose toxicity owing to their
high local concentration of the galactose-metabolising enzyme
galactose-1-phosphate uridyltransferase, as well as their high
tissue-specific activity of this enzyme (Xu et al, 1989; Larsson
et al, 2004). Galactose is believed to be ootoxic or to induce high
concentrations of gonadotropins (Cramer, 1989; Cramer et al,
1989). Although in three prospective studies no statistically
significant associations between all epithelial ovarian cancers and
lactose intake has been reported (Kushi et al, 1999; Fairfield et al,
2004; Larsson et al, 2004), two of these studies did suggest that
lactose might adversely affect serous ovarian cancer risk (Fairfield
et al, 2004; Larsson et al, 2004). Our study results however suggest
no association with lactose intake or might even indicate an
inverse association. Inverse associations between lactose intake
and ovarian cancer have previously been reported from case–
control studies (Herrinton et al, 1995; Goodman et al, 2002).
Differences in level of lactose intake may have contributed to the
discrepancy among cohort studies, since the Netherlands has a
high consumption of dairy products. However, categories of
lactose intake did not differ largely among these studies although
the median intake in the lowest categories was somewhat higher in
the present Dutch than in the Swedish or US studies. The
comparable number of ovarian cancer cases as well as of the serous
subtype in the cohort studies would not explain the negative
findings of the present study. Although height was found to be a
risk factor in our cohort (Schouten et al, 2003), omitting height
from the multivariate model did not change the RRs for total milk
consumption or for lactose intake. Moreover, when included in the
models, the interaction terms (height*lactose and height*total
milk, respectively) did not reach statistical significance, thereby
excluding height as an effect modifier. On the other hand, dairy fat
intake was associated with risk in our study; women in the highest
quintile of dairy fat intake were at 1.53 (95% CI¼1.00–2.36) times
higher risk than those in the lowest quintile. In 1990, Mettlin and
Piver suggested that it was not the lactose content of milk but
rather its fat content that was responsible for the association. High
consumption of fat may influence ovarian cancer risk through
increased oestrogen levels (Qin et al, 2005). Since this effect was
absent for serous ovarian cancer, we hypothesise that dairy fat may
present a risk for ovarian cancers other than serous, such as the
endometrioid subtype, but their small number (n¼24) did not
allow for separate analysis.
Consumption of fermented dairy products was not associated
with risk in our study. Fermented milk bacteria potentially have
protective effects, because they provide a detoxification mecha-
nism through the binding of heterocyclic aromatic amines directly
to their cell walls (Knasmuller et al, 2001). Milk and other dairy
products however also contain calcium and various vitamins, and
moreover may be contaminated by pesticides; none of these were
covered in the present study.
The important strengths of our study are its prospective design,
reducing the potential for recall bias and the nearly complete
follow-up of cases as well as of subcohort members, making
selection bias unlikely. Moreover, we were able to control for
confounding by most known ovarian cancer risk factors.
Measurement error may have influenced our results, but we
expect this to be random and to have at most biased our results
towards the null. In addition, multivariate modelling itself may
have added some uncertainty through measurement error affecting
confounders as well (Schatzkin and Kipnis, 2004). We used a food
frequency questionnaire to measure consumption of milk and
milk products, which, in a validation study, was found to correlate
well with a 9-day diet record (Goldbohm et al, 1994a). There was
a relatively high correlation between lactose and total milk
(r¼0.73), but the risk estimate with lactose intake did not
importantly change when milk consumption was included in the
analysis. In addition, adjusting for dietary fat or total energy did
not significantly change the RR for lactose.
In this prospective cohort study of postmenopausal women,
consumption of milk, yoghurt or cheese was not associated with
ovarian cancer risk. Contrary to previous findings, lactose intake
was not associated with risk of serous ovarian cancer or even
showed a slight inverse association. The highest quintile of dairy
fat intake was associated with overall, but not with serous, ovarian
cancer risk when compared to the lowest intake.
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